CADTH is inviting stakeholder comments on proposed changes to the patient input template for the CADTH Common Drug Review (CDR) and the pan-Canadian Oncology Drug Review (pCODR). Patient input is used by CADTH review teams and by the expert committees of the CDR and pCODR programs: the CADTH Canadian Drug Expert Committee (CDEC) or the pCODR Expert Review Committee (pERC).
We’re aware of how much time and effort patient groups invest in collecting data and preparing patient input submissions. After looking carefully at how patient input is used by CADTH and reflecting on comments received from patient groups, CADTH staff, and committee members over time, we’re proposing revisions to our patient input templates for both programs. The objective is to help improve the quality of Canadian health technology assessment drug processes.
- In response to your comments, we have provided a brief explanation, for each section, on how CADTH will use your insights and experiences
- Greater focus on treatment rather than disease, which reflects the scope of our drug assessments and the mandate of the expert committees
- Caregiver views are included for each question, reflecting how patients and caregivers both share their thoughts and experiences to you.
- Updated conflict of interest declaration form, which will be identical across both processes. For both processes, dollar amounts will be redacted from the conflict of interest declaration form when the document is publicly posted on CADTH’s website.
For more information about the proposed changes, please see the CDR and pCODR Patient Input Template.
Why patient input is important:
Insights, perspectives, and experiences from patient group submissions are used to:
- Identify the outcomes upfront that are most important to patients when establishing the plan (protocol) for conducting the review
- Understand insights and information unavailable through other sources, such as patient-reported outcomes and quality-of-life data
- Help CADTH reviewers interpret and apply data emerging from clinical trials, including relevance in a Canadian health care setting
- Offer specific ways that current therapies may fall short, to better understand the potential value of new therapies
- Offer new and different scenarios about the drug under review
CADTH welcomes your feedback on our proposed revisions to the patient input templates. From September 12 to October 25, 2016, patient groups are invited to comment on our proposed templates. Please use the feedback form and email to email@example.com. All feedback submitted by the deadline will be carefully considered and used to inform the final templates, targeted for use in December 2016.